The objective was to chemosensitize tumor cells, with a reduced expression of OATP1B1 (MOC-1a) and a high expression of MRP2 (MOC-1b), to antitumor drugs efficiently transported by OATP1B1. This evidence concerns the gene SLCO1B1 and neoplasm.